Home / Publication / Towards a Best Practice Approach in PBPK Modeling: Case Example of Developing a Unified Efavirenz Model Accounting for Induction of CYPs 3A4 and 2B6

論文

Towards a Best Practice Approach in PBPK Modeling: Case Example of Developing a Unified Efavirenz Model Accounting for Induction of CYPs 3A4 and 2B6

Author(s): Alice Ke, Zoe Barter, Karen Rowland-Yeo, Lisa Almond

Year: 2016年7月20日

Redefining Regulatory Strategy with MIDD: Insights from the Draft ICH M15 Guidance

ブログ

Powered by Translations.com GlobalLink Web Software

Towards a Best Practice Approach in PBPK Modeling: Case Example of Developing a Unified Efavirenz Model Accounting for Induction of CYPs 3A4 and 2B6

Towards a Best Practice Approach in PBPK Modeling: Case Example of Developing a Unified Efavirenz Model Accounting for Induction of CYPs 3A4 and 2B6

The Medicine Maker: The Biosimulation Generation

モデルを活かした医薬品開発 (MIDD) が医薬品開発の危機的状況をどのように救ったか

How is the pharmaceutical industry addressing global health inequities?

Redefining Regulatory Strategy with MIDD: Insights from the Draft ICH M15 Guidance

メルマガ登録

クイックアクセス

ソリューション

お問合せ